一个新的RAGE调节器诱导可溶性RAGE来减少阿尔茨海默病中BACE1的表达
Seung-Hyun Baek1, Suji Hong1, Eunae Kim1
1School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 5, 2025
概括
抗癌药物6-thioguanosine (6-TG) 在阿尔茨海默病 (AD) 模型中降低了β-分泌酶 (BACE1). 这种方法通过降低粉样β积累和改善认知功能来减轻AD病理.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- β-分泌酶 (BACE1) 驱动了粉样β (Aβ) 的产生,这与阿尔茨海默病 (AD) 有关.
- 氨基酸β与高级糖化终产品 (RAGE) 受体的相互作用会恶化神经毒性和神经炎症,增加BACE1.
- 之前的BACE1抑制策略遇到了局限性.
研究的目的:
- 研究降低BACE1表达的潜力,以减轻AD病理.
- 探索抗癌药物6-thioguanosine (6-TG) 对AD的治疗作用.
- 阐明6 - TG在AD中的作用背后的分子机制.
主要方法:
- 利用深度学习来识别目标.
- 采用表面等离子体共振测试来确认分子相互作用.
- 在AD小鼠模型中评估BACE1表达,微质细胞化,认知功能和Aβ积累.
- 研究了JAK2-STAT1通路和可溶性RAGE (sRAGE) 水平.
主要成果:
- 6 - 瓜素 (6-TG) 显著降低了BACE1的表达,没有细胞毒性.
- 在AD小鼠中,6-TG增强了微质细胞活性,改善了认知障碍.
- 6-TG减少了Aβ积累,并直接与RAGE相互作用,通过JAK2-STAT1通路调节BACE1.
- 观察到大脑中可溶性RAGE (sRAGE) 水平升高.
结论:
- 6-TG证明了改善阿尔茨海默病表现的治疗潜力.
- 通过像6-TG这样的小分子准BACE1表达,为AD治疗提供了一个可行的策略.
- 增加大脑SRAGE水平为AD提供了一个有希望的治疗途径,绕过直接BACE1抑制的挑战.
相关概念视频
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


